Cargando…

B7-H3/CD276: An Emerging Cancer Immunotherapy

Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Wu-Tong, Jin, Wei-Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326801/
https://www.ncbi.nlm.nih.gov/pubmed/34349762
http://dx.doi.org/10.3389/fimmu.2021.701006
_version_ 1783731923728728064
author Zhou, Wu-Tong
Jin, Wei-Lin
author_facet Zhou, Wu-Tong
Jin, Wei-Lin
author_sort Zhou, Wu-Tong
collection PubMed
description Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy.
format Online
Article
Text
id pubmed-8326801
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83268012021-08-03 B7-H3/CD276: An Emerging Cancer Immunotherapy Zhou, Wu-Tong Jin, Wei-Lin Front Immunol Immunology Immunotherapy aiming at suppressing tumor development by relying on modifying or strengthening the immune system prevails among cancer treatments and points out a new direction for cancer therapy. B7 homolog 3 protein (B7-H3, also known as CD276), a newly identified immunoregulatory protein member of the B7 family, is an attractive and promising target for cancer immunotherapy because it is overexpressed in tumor tissues while showing limited expression in normal tissues and participating in tumor microenvironment (TME) shaping and development. Thus far, numerous B7-H3-based immunotherapy strategies have demonstrated potent antitumor activity and acceptable safety profiles in preclinical models. Herein, we present the expression and biological function of B7-H3 in distinct cancer and normal cells, as well as B7-H3-mediated signal pathways in cancer cells and B7-H3-based tumor immunotherapy strategies. This review provides a comprehensive overview that encompasses B7-H3’s role in TME to its potential as a target in cancer immunotherapy. Frontiers Media S.A. 2021-07-19 /pmc/articles/PMC8326801/ /pubmed/34349762 http://dx.doi.org/10.3389/fimmu.2021.701006 Text en Copyright © 2021 Zhou and Jin https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Zhou, Wu-Tong
Jin, Wei-Lin
B7-H3/CD276: An Emerging Cancer Immunotherapy
title B7-H3/CD276: An Emerging Cancer Immunotherapy
title_full B7-H3/CD276: An Emerging Cancer Immunotherapy
title_fullStr B7-H3/CD276: An Emerging Cancer Immunotherapy
title_full_unstemmed B7-H3/CD276: An Emerging Cancer Immunotherapy
title_short B7-H3/CD276: An Emerging Cancer Immunotherapy
title_sort b7-h3/cd276: an emerging cancer immunotherapy
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8326801/
https://www.ncbi.nlm.nih.gov/pubmed/34349762
http://dx.doi.org/10.3389/fimmu.2021.701006
work_keys_str_mv AT zhouwutong b7h3cd276anemergingcancerimmunotherapy
AT jinweilin b7h3cd276anemergingcancerimmunotherapy